Breaking News

Frontage Expands Early Drug Discovery Services

Acquires majority stake in Wuhan Heyan Biomedical Technology.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Frontage Shanghai has expanded its early drug discovery services through the acquisition of 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd. Heyan Biotech, located in Wuhan Optics Valley, national biotech industry base, provides for target based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic evaluation services in early drug discovery. Technical capabilities include screening of drug targets, customized biological assay development and detection se...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters